Physician profile
Sidney Thomas Robin
NPI 1760499586
$2,270.95
in general payments reported to CMS, 2019-2025
18 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $196 · 2021: $224 · 2022: $209 · 2023: $388 · 2024: $395 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $749.36 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $356.14 | 2022-2025 | |
| Amgen INC. | $331.63 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $215.65 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $150.58 | 2022-2024 | Farxiga |
| Idorsia Pharmaceuticals US INC | $133.18 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $55.44 | 2020-2023 | Arexvy, Shingrix |
| Abbvie INC. | $53.75 | 2021-2023 | Qulipta |
| Heartflow, INC. | $47.03 | 2024 | |
| Novartis Pharmaceuticals Corporation | $33.16 | 2022 | |
| Althera Pharmaceuticals LLC | $32.58 | 2021 | |
| Pfizer INC. | $28.71 | 2024 | |
| Alk-Abello, INC | $25.96 | 2024 | Odactra, Ragwitek, Grastek |
| Astellas Pharma US INC | $15.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.74 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.30 | 2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Robin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.